Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Icatibant acetate (Firazyr®) is recommended as an option for use within NHS Wales for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. |
|||
|
|||
Medicine details |
|||
| Medicine name | icatibant acetate (Firazyr®) | ||
| Formulation | 30 mg solution for injection | ||
| Reference number | 3293 | ||
| Indication | Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase-inhibitor deficiency |
||
| Company | Shire Pharmaceuticals | ||
| BNF chapter | Respiratory system | ||
| Assessment type | Limited | ||
| Status | Recommended | ||
| Advice number | 0818 | ||
| NMG meeting date | 11/04/2018 | ||
| AWMSG meeting date | 23/05/2018 | ||
| Date of issue | 12/06/2018 | ||
| Date of last review | December 2021 | ||
| Commercial arrangement | WPAS | ||